UK’s MHRA seizes £8.6 million of counterfeit, controlled and unlicensed medicines

26 May 2014

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) revealed last week that it has seized £8.6 million ($14.5 million) of counterfeit and unlicensed medicines in the UK, including huge hauls of potentially harmful slimming pills and controlled drugs such as diazepam and anabolic steroids.

This was part of a week-long international crackdown on the illegal internet trade of medicines that resulted in seizures totalling around £18.6 million globally.

The crackdown, coordinated through Interpol – called Operation Pangea VII - was conducted between May 11 and May 21 and resulted in 237 people being arrested worldwide. This operation also targeted 10,603 web sites that were illegally selling counterfeit and unlicensed medicines and led to them being closed down or suspended through having their domain name or payment facility removal.

Shutdown of 1,891 web sites

In the UK, enforcement officers from the MHRA, with assistance from Home Office Border Force and local police, raided addresses in connection with the illegal internet supply of potentially harmful medicines. This UK activity resulted in the seizure of 3.6 million doses of counterfeit and unlicensed medicines, five arrests and the shutdown of 1,891 web sites.

A breakdown of the UK seizures highlights the trend towards lifestyle medications that are unlicensed, adulterated or controlled under the Misuse of Drugs Act 1971. The most commonly seized drugs were: erectile dysfunction treatments (1.2 million doses), slimming products (383,000) and powerful and often misused drugs like sleeping pills, tranquilisers and antidepressants (330,996 doses). The majority of packages seized that contained medicines supplied illegally originated from India and China, with 72% and 11% of seizures originating from these countries, respectively, said the MHRA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical